Enovis Corporation (ENOV)

NYSE · Medical Devices

26.64
+1.00 (+3.90%)
Updated Aug 19, 5:44 PM ET
AI Rating
Hold
Overall Score
52
Trend
68
Momentum
36
Risk
48

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Feb 24, 2026 120 sessions Aug 14, 2026

AI Analysis

Enovis Corporation is trading at $26.64, up 3.90% on the session. The 50 day average sits at $24.93 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 48.4, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $25.40 with resistance near $26.50, so that band frames the current range. Average daily movement is roughly $1.59, or about 6.0% of the share price, which is what any stop placement has to allow for. The overall health score of 52 out of 100 combines a trend score of 68, momentum of 36 and a risk score of 48.

Technical indicators

RSI (14)
48.4
neutral
MACD
0.039
bearish crossover
SMA 20
27.53
SMA 50
24.93
SMA 200
--
unknown
ATR (14)
1.59
avg daily range
Support
25.40
Resistance
26.50
Volume vs 20d
0.72x
below average
Volatility
76.2%
annualised
1 month
-7.16%
3 months
-0.23%

About Enovis Corporation

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.